Molecular targeted therapy in acute myeloid leukemia

Naval Daver, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding the biology of this disease and identification of driver mutations has ushered in a new era of molecular therapeutics. Although a number of molecular markers and pathways have been identified and may serve as potential therapeutic targets, the best studied amongst these include FMS like tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus kinase (JAK-2). In this review we discuss the molecular biology of AML, with a special focus on the above mentioned pathways. We discuss novel molecular targeted therapies that are in preclinical and clinical development. These include AC-220, sorafenib and midostaurin in FLT3 mutated patients; GSK1120212 and MSC1936369B in RAS mutated patients; and INCB018424 in JAK2 mutated patients. Identification of such molecular mutations and appropriate use of targeted therapies, either alone or in combinations, may eventually revolutionize the treatment of AML.

Original languageEnglish (US)
Pages (from-to)S59-S62
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Acute Myeloid Leukemia
4'-N-benzoylstaurosporine
Protein-Tyrosine Kinases
Janus Kinase 2
MAP Kinase Kinase Kinases
Therapeutics
Mutation
Molecular Biology

Keywords

  • Acute myeloid leukemia
  • FLT3 protein
  • JAK2
  • RAS

ASJC Scopus subject areas

  • Hematology

Cite this

Molecular targeted therapy in acute myeloid leukemia. / Daver, Naval; Cortes, Jorge.

In: Hematology, Vol. 17, No. SUPPL. 1, 01.04.2012, p. S59-S62.

Research output: Contribution to journalReview article

Daver, Naval ; Cortes, Jorge. / Molecular targeted therapy in acute myeloid leukemia. In: Hematology. 2012 ; Vol. 17, No. SUPPL. 1. pp. S59-S62.
@article{4c63ea9929284fe2ad8796f9c4ed0967,
title = "Molecular targeted therapy in acute myeloid leukemia",
abstract = "The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding the biology of this disease and identification of driver mutations has ushered in a new era of molecular therapeutics. Although a number of molecular markers and pathways have been identified and may serve as potential therapeutic targets, the best studied amongst these include FMS like tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus kinase (JAK-2). In this review we discuss the molecular biology of AML, with a special focus on the above mentioned pathways. We discuss novel molecular targeted therapies that are in preclinical and clinical development. These include AC-220, sorafenib and midostaurin in FLT3 mutated patients; GSK1120212 and MSC1936369B in RAS mutated patients; and INCB018424 in JAK2 mutated patients. Identification of such molecular mutations and appropriate use of targeted therapies, either alone or in combinations, may eventually revolutionize the treatment of AML.",
keywords = "Acute myeloid leukemia, FLT3 protein, JAK2, RAS",
author = "Naval Daver and Jorge Cortes",
year = "2012",
month = "4",
day = "1",
doi = "10.1179/102453312X13336169155619",
language = "English (US)",
volume = "17",
pages = "S59--S62",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Molecular targeted therapy in acute myeloid leukemia

AU - Daver, Naval

AU - Cortes, Jorge

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding the biology of this disease and identification of driver mutations has ushered in a new era of molecular therapeutics. Although a number of molecular markers and pathways have been identified and may serve as potential therapeutic targets, the best studied amongst these include FMS like tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus kinase (JAK-2). In this review we discuss the molecular biology of AML, with a special focus on the above mentioned pathways. We discuss novel molecular targeted therapies that are in preclinical and clinical development. These include AC-220, sorafenib and midostaurin in FLT3 mutated patients; GSK1120212 and MSC1936369B in RAS mutated patients; and INCB018424 in JAK2 mutated patients. Identification of such molecular mutations and appropriate use of targeted therapies, either alone or in combinations, may eventually revolutionize the treatment of AML.

AB - The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding the biology of this disease and identification of driver mutations has ushered in a new era of molecular therapeutics. Although a number of molecular markers and pathways have been identified and may serve as potential therapeutic targets, the best studied amongst these include FMS like tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus kinase (JAK-2). In this review we discuss the molecular biology of AML, with a special focus on the above mentioned pathways. We discuss novel molecular targeted therapies that are in preclinical and clinical development. These include AC-220, sorafenib and midostaurin in FLT3 mutated patients; GSK1120212 and MSC1936369B in RAS mutated patients; and INCB018424 in JAK2 mutated patients. Identification of such molecular mutations and appropriate use of targeted therapies, either alone or in combinations, may eventually revolutionize the treatment of AML.

KW - Acute myeloid leukemia

KW - FLT3 protein

KW - JAK2

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=84859768494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859768494&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169155619

DO - 10.1179/102453312X13336169155619

M3 - Review article

C2 - 22507781

AN - SCOPUS:84859768494

VL - 17

SP - S59-S62

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -